Clinical Trial Update: Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer

View source ↗

Summary

This clinical trial update reports termination of a study evaluating urokinase plasminogen activator receptor in abiraterone-treated castration-resistant prosta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

Sponsor: Kristoffer Rohrberg | Conditions: Prostatic Neoplasms | Status: TERMINATED